Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relday vs Risperdal Consta in Schizophrenia
NCT02411526Phase 1Completed
- Sponsor
- Zogenix, Inc.
- Start
- Feb 2015
- Primary completion
- Sep 2015
- Countries
- 1
01
Overview
Phase 1, open-label trial in schizophrenia and schizoaffective disorder (4 cohorts), sponsored by Zogenix, Inc. Primary endpoint: Pharmacokinetic profile of ZX003. Started Feb 2015; status: completed.
02
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02411526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411526.